Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Item
http://www.wikidata.org/entity/Q36574920
Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current EvidenceERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Enrichment and Molecular Analysis of Breast Cancer Disseminated Tumor Cells from Bone Marrow Using Microfiltration.Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early Stage Lung Cancers.Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?Circulating and disseminated tumor cells: harbingers or initiators of metastasis?Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.Involvement of breast cancer stem cells in tumor angiogenesis.Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer.Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.The Inner and Outer Qualities of Extracellular Vesicles for Translational Purposes in Breast Cancer.Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer
P2860

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Item
http://www.wikidata.org/entity/Q36574920
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Does primary neoadjuvant syste ...... cells before and after therapy
@ast
Does primary neoadjuvant syste ...... cells before and after therapy
@en
type
label
Does primary neoadjuvant syste ...... cells before and after therapy
@ast
Does primary neoadjuvant syste ...... cells before and after therapy
@en
prefLabel
Does primary neoadjuvant syste ...... cells before and after therapy
@ast
Does primary neoadjuvant syste ...... cells before and after therapy
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Does primary neoadjuvant syste ...... cells before and after therapy
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P921
P932